rap103
Peptideexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Oct 1, 2025 (NCT07204639)
Timeline
2020s
- Jan 1, 2025
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- C-C chemokine receptor type 5INHIBITOR
CCR5 inhibitor
- C-C chemokine receptor type 2INHIBITOR
CCR2 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07204639 | Phase 2 | Oct 1, 2025 | Clarent Biopharma, Inc., Hospital General Dr. Manuel Gea Gonzalez |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Clarent Biopharma, Inc. | For profit | 1 | 1 | 1 | 2025 |
| Hospital General Dr. Manuel Gea Gonzalez | Academic/Hospital | 1 | 0 | 1 | 2025 |
2 organizations
Page 1 / 1